ASH 2020 | Real-world use of carfilzomib for R/R myeloma patients
Evangelos Terpos, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, outlines the results of an interim analysis of carfilzomib (K) efficacy and safety in relapsed/refractory (R/R) multiple myeloma, as part of a large prospective observational investigation (NCT03091127). 701 patients who had received K-based regimes were analyzed. 55% received K, lenalidomide, and dexamethasone (KRd), and 39% received K and dexamethasone alone (Kd). Patients treated with Kd were typically older and frailer than KRd patients. They were also more heavily pre-treated with a median of 3 prior lines, compared to 1 in the KRd group. The benefit-risk profile for both regimens fitted with earlier clinical trial results. Deeper responses were achieved in earlier lines of therapy for both groups, affirming the need for MM therapy optimization. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
